The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis. A serial diffusion MRI study

Brain

Volumn 123, Issue 8, 2000, Pages 1667-1676

  Werring, D J ^a   Brassat, D ^b   Droogan, A G ^a   Clark, C A ^a   Symms, M R ^a   Barker, G J ^a   MacManus, D G ^a   Thompson, A J ^a   Miller, D H ^a,c  

^a NMR Research Unit   (United Kingdom)

^b CHU PURPAN   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diffusion; Magnetic resonance imaging; Multiple sclerosis; Pathophysiology

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN DYSFUNCTION; BRAIN INJURY; BRAIN WATER; CLINICAL ARTICLE; CLINICAL TRIAL; DIFFUSION; FEMALE; HUMAN; IMAGE ENHANCEMENT; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOISOTOPE DECAY; WATER FLOW; WHITE MATTER;

EID: 0033909486     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.8.1667     Document Type: Article

References (48)

1. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41: 81-91.
2. Anderson AW, Gore JC. Analysis and correction of motion artifacts in diffusion weighted imaging. Magn Reson Med 1994; 32: 379-87.
3. Berry I, Barker GJ, Barkhof F, Campi A, Dousset V, Franconi JM, et al. A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging 1999; 9: 441-6.
4. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. [Review]. Neurosci Biobehav Rev 1989; 13: 23-31.
5. Bruck W. Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
6. Christiansen P, Gideon P, Thomsen C, Stubgaard M, Henriksen O, Larsson HB. Increased water self-diffusion in chronic plaques and in apparently normal white matter in patients with multiple sclerosis. Acta Neurol Scand 1993; 87: 195-9.
7. Clanet M, Berry I. Magnetic resonance imaging in multiple sclerosis. [Review]. Curr Opin Neurol 1998; 11: 299-303.
8. de Lacoste MC, Kirkpatrick JB, Ross ED. Topography of the human corpus callosum. J Neuropathol Exp Neurol 1985; 44: 578-91.
9. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999; 122: 1933-9.
10. Dousset V, Gayou A, Brochet B, Caille JM. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology 1998; 51: 1150-5.
11. Droogan AG, Clark CA, Werring DJ, Barker GJ, McDonald WI, Miller DH. Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging. Magn Reson Imaging 1999; 17: 653-61.
12. Evangelou N, Esiri M, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-5.
13. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
14. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996; 46: 379-84.
15. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43: 809-14.
16. Gallagher HL, MacManus DG, Webb SL, Miller DH. A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis. J Magn Reson Imaging 1997; 7: 439-41.
17. Gass A, Moeckel R, Hirsch J, Hennerici MG, Schwartz A. Diffusion MRI characterisation of MS lesion evolution [abstract]. Multiple Sclerosis 1999; 5 Suppl 1: S21.
18. Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998; 51: 1689-97.
19. Hand D, Crowder M. Practical longitudinal data analysis. London: Chapman & Hall; 1996.
20. Heide AC, Richards TL, Alvord EC Jr, Peterson J, Rose LM. Diffusion imaging of experimental allergic encephalomyelitis. Magn Reson Med 1993; 29: 478-84.
21. Horsfield MA, Lai M, Webb SL, Barker GJ, Tofts PS, Turner R, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med 1996; 36: 393-400.
22. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-9.
23. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229-35.
24. Kuhn MJ, Mikulis DJ, Ayoub DM, Kosofsky BE, Davis KR, Taveras JM. Wallerian degeneration after cerebral infarction: evaluation with sequential MR imaging. Radiology 1989; 172: 179-82.
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
26. Larsson HB, Thomsen C, Frederiksen J, Stubgaard M, Henriksen O. In vivo magnetic resonance diffusion measurement in the brain of patients with multiple sclerosis. Magn Reson Imaging 1992; 10: 7-12.
27. Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerk H, editors. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone; 1998. p. 323-58.
28. Le Bihan D, Turner R, Doueck P, Patronas N. Diffusion MR imaging: clinical applications. [Review]. AJR Am J Roentgenol 1992; 159: 591-9.
29. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46: 907-11.
30. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. [Review]. Brain Pathol 1996; 6: 259-74.
31. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. [Review]. Neuropathol Appl Neurobiol 1992; 18: 319-34.
32. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-39.
33. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225-37.
34. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56-71.
35. Ordidge RJ, Helpern JA, Qing ZX, Knight RA, Nagesh V. Correction of motional artifacts in diffusion-weighted MR images using navigator echoes. Magn Reson Imaging 1994; 12: 455-60.
36. Pike GB, De Stefano N, Narayanan S, Francis G, Antel J, Arnold DL. A longitudinal study of magnetization transfer in multiple sclerosis [abstract]. Proc Int Soc Magn Reson Med 1998; 1: 122.
37. Poser CM, Paty DW, Scheinberg L, McDonald; WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
38. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997; 120: 1149-61.
39. Silver NC, Lai M, Symms MR, Barker GJ, McDonald WI, Miller DH. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 1998; 51: 758-64.
40. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60-3.
41. Tourtellotte WW, Parker JA. Some spaces and barriers in postmortem multiple sclerosis. Prog Brain Res 1968; 29: 493-525.
42. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
43. van Waesberghe JH, Castelijns JA, Roser W, Silver N, Yousry T, Lycklama a Nijeholt GJ, et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997; 18: 1279-85.
44. Verhoye MR, 's-Gravenmade EJ, Raman ER, Van Reempts J, Van der Linden A. In vivo noninvasive determination of abnormal water diffusion in the rat brain studied in an animal model for multiple sclerosis by diffusion-weighted NMR imaging. Magn Reson Imaging 1996; 14: 521-32.
45. Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999; 52: 1626-32.
46. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43-9.
47. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16: 620-33.
48. Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2: 1063-6.